Patent ID: 8252524

Claim:
A method of screening for a pharmaceutical composition for treatment of arteriosclerosis, comprising: adding a test substance to a first human umbilical vein endothelial cells (HUVECs) culture which comprises HUVECs expressing Cdc42 fusion protein comprising a fluorescent protein, culturing a second HUVECs culture which comprises HUVECs expressing the Cdc42 fusion protein comprising the fluorescent protein, culturing said first and second HUVECs culture for a sufficient time for the fluorescent Cdc42 fusion protein to transfer into the nucleus, said first HUVECs culture being cultured in the presence of the test substance and said second HUVECs culture being cultured in the absence of the test substance, measuring distribution of the amount of fluorescence in said first HUVECs culture and said second HUVECs culture, and determining, if the distribution of fluorescence in the nucleus of said first HUVECs culture is greater than the distribution of fluorescence in the nucleus of said second HUVECs culture, thereby identifying a pharmaceutical composition suitable for the treatment of arteriosclerosis.